Adult medulloblastoma: a case report.
Case report
Chemotherapy
Craniospinal radiation
Medulloblastoma
Ocean Road Cancer Institute
Posterior cranial fossa
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
25 Aug 2022
25 Aug 2022
Historique:
received:
23
03
2022
accepted:
18
07
2022
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Medulloblastoma is a malignant brain tumor that is common in children but very uncommon in adults, especially those older than 40 years, accounting for less than 1% of all primary brain tumors in adults. Although surgery and radiotherapy play an important role treatment of adult medulloblastoma, the use of chemotherapy is controversial. This is the first instance of adult medulloblastoma at the Ocean Road Cancer Institute in Tanzania. We report the case of a 51-year-old female of African ethnicity who was diagnosed with high-risk hemispheric posterior cranial fossa medulloblastoma of classic type with World Health Organization central nervous system grade 4 and Chang stage M0. Immunohistochemistry, reticulin stain, and molecular subtyping could not be done because they were not available. She was treated by subtotal posterior cranial fossa tumor resection followed by adjuvant concurrent chemo-craniospinal radiation and adjuvant chemotherapy. Even in adults over 50 years old, medulloblastoma should be included in the differential diagnosis of posterior fossa tumor. Adult medulloblastoma is a very rare and very heterogeneous tumor, but it has a good prognosis. Immunohistochemistry and molecular subclustering are difficult to implement in low-income countries such as Tanzania owing to cost. Treatment of adult medulloblastoma is highly heterogeneous among (and even within) facilities. There is no evidence that the extent of resection enhances survival. While craniospinal radiation therapy improves survival, there is controversy about the role of chemotherapy in managing adult MB.
Sections du résumé
BACKGROUND
BACKGROUND
Medulloblastoma is a malignant brain tumor that is common in children but very uncommon in adults, especially those older than 40 years, accounting for less than 1% of all primary brain tumors in adults. Although surgery and radiotherapy play an important role treatment of adult medulloblastoma, the use of chemotherapy is controversial. This is the first instance of adult medulloblastoma at the Ocean Road Cancer Institute in Tanzania.
CASE DESCRIPTION
METHODS
We report the case of a 51-year-old female of African ethnicity who was diagnosed with high-risk hemispheric posterior cranial fossa medulloblastoma of classic type with World Health Organization central nervous system grade 4 and Chang stage M0. Immunohistochemistry, reticulin stain, and molecular subtyping could not be done because they were not available. She was treated by subtotal posterior cranial fossa tumor resection followed by adjuvant concurrent chemo-craniospinal radiation and adjuvant chemotherapy.
CONCLUSION
CONCLUSIONS
Even in adults over 50 years old, medulloblastoma should be included in the differential diagnosis of posterior fossa tumor. Adult medulloblastoma is a very rare and very heterogeneous tumor, but it has a good prognosis. Immunohistochemistry and molecular subclustering are difficult to implement in low-income countries such as Tanzania owing to cost. Treatment of adult medulloblastoma is highly heterogeneous among (and even within) facilities. There is no evidence that the extent of resection enhances survival. While craniospinal radiation therapy improves survival, there is controversy about the role of chemotherapy in managing adult MB.
Identifiants
pubmed: 36002876
doi: 10.1186/s13256-022-03531-3
pii: 10.1186/s13256-022-03531-3
pmc: PMC9404560
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
330Informations de copyright
© 2022. The Author(s).
Références
J Clin Neurosci. 2012 Nov;19(11):1541-4
pubmed: 22981874
Lancet Oncol. 2016 Apr;17(4):484-495
pubmed: 26976201
J Korean Neurosurg Soc. 2018 May;61(3):292-301
pubmed: 29742881
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):147-54
pubmed: 9747832
Radiology. 1969 Dec;93(6):1351-9
pubmed: 4983156
Crit Rev Oncol Hematol. 2009 Aug;71(2):165-79
pubmed: 19303318
Neurooncol Adv. 2021 Jun 22;3(1):vdab079
pubmed: 34377987
Cancer. 1994 Oct 15;74(8):2352-60
pubmed: 7922986
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Cancer. 2008 Apr 1;112(7):1568-74
pubmed: 18278809
BMC Cancer. 2020 Aug 12;20(1):755
pubmed: 32787805
J Clin Oncol. 2003 Apr 15;21(8):1581-91
pubmed: 12697884
Neuro Oncol. 2016 Mar;18(3):408-16
pubmed: 26359208
Neuro Oncol. 2016 Jul;18(7):982-90
pubmed: 27106407
Cancer. 2007 Nov 1;110(9):2035-41
pubmed: 17823910
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79
pubmed: 10661332
Curr Treat Options Oncol. 2019 Jun 24;20(8):64
pubmed: 31236711
Eur J Cancer. 2013 Mar;49(4):893-903
pubmed: 23182688
Neuro Oncol. 2017 Feb 1;19(2):259-269
pubmed: 27540083